Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.

[1]  J. Pope,et al.  Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. , 2011, Arthritis and rheumatism.

[2]  Brian T Fay,et al.  Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. , 2011, Rheumatology.

[3]  W. Dixon,et al.  No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register , 2010, Arthritis and rheumatism.

[4]  S. Gabriel,et al.  Epidemiology of Rheumatoid Arthritis: Rheumatoid Arthritis and Mortality , 2010, Current rheumatology reports.

[5]  N. Stavrianeas,et al.  Development of Two Primary Malignant Melanomas after Treatment with Adalimumab: A Case Report and Review of the Possible Link between Biological Therapy with TNF-α Antagonists and Melanocytic Proliferation , 2010, Dermatology.

[6]  L. Virta,et al.  No increased mortality in incident cases of rheumatoid arthritis during the new millennium , 2010, Annals of the rheumatic diseases.

[7]  J. Fransen,et al.  Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis , 2010, Arthritis care & research.

[8]  L. Jacobsson,et al.  Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? , 2009, Arthritis and rheumatism.

[9]  D. Blazer,et al.  Identifying a national death index match. , 2009, American journal of epidemiology.

[10]  T. Einarson,et al.  The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events , 2008, Annals of the rheumatic diseases.

[11]  E. Matteson,et al.  Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials , 2008, Annals of the rheumatic diseases.

[12]  M. Khraishi.  Comparative Overview of Safety of the Biologics in Rheumatoid Arthritis , 2009, The Journal of Rheumatology.

[13]  T. Pincus,et al.  Mortality in rheumatoid arthritis: 2008 update. , 2008, Clinical and experimental rheumatology.

[14]  M. Leirisalo-Repo,et al.  Causes of death in patients with rheumatoid arthritis autopsied during a 40-year period , 2008, Rheumatology International.

[15]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[16]  J. Askling,et al.  Malignancy and biologic therapy in rheumatoid arthritis , 2008, Current opinion in rheumatology.

[17]  W. Dixon,et al.  The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis , 2008, Current opinion in rheumatology.

[18]  S. Gabriel,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. , 2008, Arthritis and rheumatism.

[19]  T. Therneau,et al.  The widening mortality gap between rheumatoid arthritis patients and the general population. , 2007, Arthritis and rheumatism.

[20]  Sebastian Schneeweiss,et al.  Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis , 2007 .

[21]  J. Allison,et al.  Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. , 2007, Arthritis and rheumatism.

[22]  E. Pérez-Pampín,et al.  All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists , 2007, Annals of the rheumatic diseases.

[23]  C. Turesson,et al.  Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[24]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[25]  Matthias Schneider,et al.  Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.

[26]  P. Laippala,et al.  Death rates and causes of death in patients with rheumatoid arthritis: a population‐based study , 2004, Scandinavian journal of rheumatology.

[27]  F. Wolfe,et al.  Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. , 2004, Arthritis and rheumatism.

[28]  S. Gabriel,et al.  Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. , 2003, Arthritis and rheumatism.

[29]  M. Greene,et al.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. , 2002, Arthritis and rheumatism.

[30]  F. Granath,et al.  Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. , 2002, The Journal of rheumatology.

[31]  K. Rothman.  Epidemiology: An Introduction , 2002 .

[32]  M. Doody,et al.  Comparability of national death index plus and standard procedures for determining causes of death in epidemiologic studies. , 2001, Annals of epidemiology.

[33]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[34]  D. Symmons,et al.  Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. , 2000, Scandinavian journal of rheumatology.